← ANALYST RATINGS · TIPRANKS
Perspective Therapeutics (CATX): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy1 Hold0 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $12.18, the highest $18.00, the lowest $5.00. The average is +461.4% from the last price of $2.17.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $14.00 | Buy | +545.2% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $2.00 → $2.50+25.0% | Hold | +15.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.00 → $2.50+25.0% | Hold | +15.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.00 → $2.50+25.0% | Hold | +15.2% | Upgrade | 16.10.26on TipRanks 18:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $2.00 → $2.50+25.0% | Hold | +15.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $2.50+25.0% | Hold | +15.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | −7.8% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | −7.8% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | −7.8% | Upgrade | 14.10.26on TipRanks 06:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Hold | −7.8% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | −7.8% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| Unknown Analyst | Wedbush | $11.00 | Buy | +406.9% | Reiterated | 13.10.26on TipRanks Oct 14 06:05 | −9.9%next day −0.2% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $11.00 | Buy | +406.9% | Reiterated | 13.10.26on TipRanks 07:50 | −9.9%next day −0.2% | ↗ |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.00 → $2.50+25.0% | Hold | +15.2% | Upgrade | 08.10.26on TipRanks 12:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Sell | −7.8% | Downgrade | 07.10.26on TipRanks 01:05 | — | |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $8.00 | Buy | +268.7% | Reiterated | 02.10.26on TipRanks Oct 3 09:35 | +0.7%next day −7.6% · 5 days −4.8% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $2.50 | Hold | +15.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $2.50 | Hold | +15.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.50 | Hold | +15.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.50 | Hold | +15.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $2.50 | Hold | +15.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 | Hold | +15.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $11.00 | Buy | +406.9% | Reiterated | 25.09.26on TipRanks Sep 26 15:05 | +0.3%next day 0.0% · 5 days +9.7% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Buy | — | Initiated | 18.09.26on TipRanks 06:20 | −0.1%next day +1.6% · 5 days −13.8% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 15.09.26on TipRanks 07:45 | −6.0%next day −0.7% · 5 days +6.1% | ↗ |
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $11.00 | Buy | +406.9% | Reiterated | 14.09.26on TipRanks Sep 15 10:25 | +4.4%next day −6.0% · 5 days −0.2% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $18.00 | Buy | +729.5% | Reiterated | 14.08.26on TipRanks 11:25 | +3.4%next day +1.1% · 5 days +4.5% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $6.00 → $5.00−16.7% | Hold | +130.4% | Reiterated | 14.08.26on TipRanks 11:15 | +3.4%next day +1.1% · 5 days +4.5% | ↗ |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | $15.00 | Buy | +591.2% | Reiterated | 11.08.26on TipRanks 15:35 | +6.3%next day +2.3% · 5 days +1.3% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $13.00 | Buy | +499.1% | Reiterated | 11.08.26on TipRanks 07:55 | +6.3%next day +2.3% · 5 days +1.3% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $16.00 → $14.00−12.5% | Buy | +545.2% | Assigned | 11.08.26on TipRanks 06:55 | +6.3%next day +2.3% · 5 days +1.3% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $14.00 | Buy | +545.2% | Reiterated | 11.08.26on TipRanks 06:55 | +6.3%next day +2.3% · 5 days +1.3% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $14.00 | Buy | +545.2% | Reiterated | 10.08.26on TipRanks Aug 11 21:45 | 0.0%next day +6.3% · 5 days +7.4% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $13.00 | Buy | +499.1% | Reiterated | 01.06.26on TipRanks 06:30 | −7.4%next day −1.8% · 5 days −17.4% | ↗ |
| Yuan Zhi★★★★★★★★★★#1180 · hits 41% · avg +20.7% | B. Riley Securities | $11.00 → $13.00+18.2% | Buy | +499.1% | Assigned | 18.03.26on TipRanks 08:55 | −0.4%next day −5.1% · 5 days −6.6% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $7.00 → $8.00+14.3% | Buy | +268.7% | Assigned | 18.03.26on TipRanks 08:10 | −0.4%next day −5.1% · 5 days −6.6% | ↗ |
| Rajan Sharma★★★★★★★★★★#5820 · hits 52% · avg +1.9% | Goldman Sachs | — | Buy | — | Reiterated | 17.02.26on TipRanks 01:45 | +3.0%next day +3.2% · 5 days +11.1% | ↗ |
| Unknown Analyst | Roth MKM | $13.00 | Buy | +499.1% | Reiterated | 25.11.25on TipRanks Nov 28 13:30 | 0.0%next day +1.1% · 5 days −0.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Perspective Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.78 at a price of $2.75 (+364.6%); now: $12.18 at $2.17 (+461.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 32 | 22 | 18 | 15 | 14 | 17 |
| Buy | 4 | 3 | 2 | 0 | 2 | 2 |
| Hold | 4 | 4 | 3 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.24 (from $-0.31 to $-0.20). Last quarter: $-0.22.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Perspective Therapeutics
- CEO: Johan Spoor
- Employees: 165
- 2401 Elliott Avenue, Seattle, WA, 98121, US
- www.perspectivetherapeutics.com
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Data from the stock’s TipRanks forecast page, read 53 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗